IMMTECH INITIATES TRIAL OF DB289 TO TREAT TRYPANOSOMIASIS
Immtech has initiated, in partnership with the University of North Carolina at Chapel Hill, a Phase III trial of its oral drug DB289 in the Democratic Republic of Congo to treat Trypanosomiasis (African sleeping sickness). The company is now screening patients for enrollment.
The study is planned at multiple sites in the Democratic Republic of Congo, Sudan and Angola. The company plans to enroll approximately 250 Stage I patients in a randomized trial, which will compare the effectiveness of DB289 to pentamidine, the current first line therapy in Africa, which is difficult to administer in remote areas and is associated with significant side effects.